Contact
searchSearch
HMP Global

Medical Therapies Topic Center

Featured Content

Research Highlights
Combination Biologic and Small-Molecule Therapy Shows Promise in Refractory IBD, Meta-Analysis Finds
01/14/2026
Jessica Garlewicz
The findings of a new analysis highlight both the potential and the caution required when considering dual-targeted therapy in patients who fail to respond to monotherapy.
The findings of a new analysis highlight both the potential and the caution required when considering dual-targeted therapy in patients who fail to respond to monotherapy.
The findings of a new analysis...
01/14/2026
Advances in Inflammatory Bowel Disease Network
FDA alert
FDA Alert
FDA Approves Updated Indication for Upadacitinib in IBD
10/14/2025
Rebecca Mashaw
The new indication allows for upadacitinib therapy among patients who have received any approved systemic therapy for IBD “in the event TNF blockers are clinically inadvisable."
The new indication allows for upadacitinib therapy among patients who have received any approved systemic therapy for IBD “in the event TNF blockers are clinically inadvisable."
The new indication allows for...
10/14/2025
Advances in Inflammatory Bowel Disease Network
Research Highlights
Real-World Effectiveness and Safety of Risankizumab in Crohn’s Disease
08/21/2025
Rebecca Mashaw
Risankizumab demonstrates sustained clinical benefit and favorable safety in Crohn’s disease, including among ustekinumab-experienced patients.
Risankizumab demonstrates sustained clinical benefit and favorable safety in Crohn’s disease, including among ustekinumab-experienced patients.
Risankizumab demonstrates...
08/21/2025
Advances in Inflammatory Bowel Disease Network
FDA Alert
FDA Approves Both SC and IV Guselkumab for Crohn's Disease Among Adult Patients
03/24/2025
Rebecca Mashaw
This clearance follows last year's approval for ulcerative colitis and the first approval for subcutaneous and intravenous formulations to induce remission in adult patients with moderately to severely active Crohn's disease.
This clearance follows last year's approval for ulcerative colitis and the first approval for subcutaneous and intravenous formulations to induce remission in adult patients with moderately to severely active Crohn's disease.
This clearance follows last...
03/24/2025
Advances in Inflammatory Bowel Disease Network
News
Study Highlights Antibody Development and Dosing Concerns in Older IBD Patients on Infliximab
01/20/2025
Jessica Garlewicz
Dosing decisions for infliximab should prioritize disease activity and patient-specific factors rather than chronological age alone.
Dosing decisions for infliximab should prioritize disease activity and patient-specific factors rather than chronological age alone.
Dosing decisions for infliximab...
01/20/2025
Advances in Inflammatory Bowel Disease Network
News
Standard Dosing of Infliximab Effective for Steroid-Refractory ASUC
10/18/2024
Jessica Garlewicz
While infliximab proved safe and effective for inducing remission in acute severe ulcerative colitis, higher doses and varied induction strategies showed no significant change in response.
While infliximab proved safe and effective for inducing remission in acute severe ulcerative colitis, higher doses and varied induction strategies showed no significant change in response.
While infliximab proved safe and...
10/18/2024
Advances in Inflammatory Bowel Disease Network
FDA alert
FDA Alert
FDA Approves Guselkumab for Moderate to Severe Ulcerative Colitis
09/12/2024
Rebecca Mashaw
Johnson & Johnson’s guselkumab is the first and only fully-human, dual-acting monoclonal antibody that blocks IL-23 and binds to CD64.
Johnson & Johnson’s guselkumab is the first and only fully-human, dual-acting monoclonal antibody that blocks IL-23 and binds to CD64.
Johnson & Johnson’s guselkumab...
09/12/2024
Advances in Inflammatory Bowel Disease Network
Christina Ha
Video
Christina Ha, MD, on the Role of Anti-interleukins in IBD
09/10/2024
Christina Ha, MD
Dr Ha reviews her presentation from the AIBD regional on the safety and efficacy of interleukin 12/23 and interleukin 23 in the management of Crohn's disease and ulcerative colitis.
Dr Ha reviews her presentation from the AIBD regional on the safety and efficacy of interleukin 12/23 and interleukin 23 in the management of Crohn's disease and ulcerative colitis.
Dr Ha reviews her presentation...
09/10/2024
Advances in Inflammatory Bowel Disease Network
IBD Drive time logo
Podcast
IBD Drive Time: Erin Forster, MD, on Risankizumab for Ulcerative Colitis
09/03/2024
Erin Forster, MD, MPH; Millie D. Long, MD, MPH; Raymond Cross, MD
Dr Erin Forster of the Medical University of South Carolina joins IBD Drive Time hosts Dr Millie Long and Dr Raymond Cross to review results of the trials for risankizumab in ulcerative colitis and discuss its positioning in treatment.
Dr Erin Forster of the Medical University of South Carolina joins IBD Drive Time hosts Dr Millie Long and Dr Raymond Cross to review results of the trials for risankizumab in ulcerative colitis and discuss its positioning in treatment.
Dr Erin Forster of the Medical...
09/03/2024
Advances in Inflammatory Bowel Disease Network
News
Subcutaneous Ustekinumab Cost Rose 84% Under Medicare Part D, Set to Drop Under Negotiated Price Reduction
08/15/2024
Rebecca Mashaw
Coverage changes omitted self-injected therapies from Part B, HHS Inspector General Reports
Coverage changes omitted self-injected therapies from Part B, HHS Inspector General Reports
Coverage changes omitted...
08/15/2024
Advances in Inflammatory Bowel Disease Network
FDA alert
FDA Alert
FDA Requires Warning Label Change for Thiopurines
08/13/2024
Rebecca Mashaw
The agency stated that rare cases of intrahepatic cholestasis of pregnancy have been reported among pregnant patients treated with thiopurines for inflammatory bowel disease and systemtic lupus erythematosus.
The agency stated that rare cases of intrahepatic cholestasis of pregnancy have been reported among pregnant patients treated with thiopurines for inflammatory bowel disease and systemtic lupus erythematosus.
The agency stated that rare...
08/13/2024
Advances in Inflammatory Bowel Disease Network

News

FDA alert
FDA Alert
FDA Approves Updated Indication for Upadacitinib in IBD
10/14/2025
Rebecca Mashaw
The new indication allows for upadacitinib therapy among patients who have received any approved systemic therapy for IBD “in the event TNF blockers are clinically inadvisable."
The new indication allows for upadacitinib therapy among patients who have received any approved systemic therapy for IBD “in the event TNF blockers are clinically inadvisable."
The new indication allows for...
10/14/2025
Advances in Inflammatory Bowel Disease Network
Research Highlights
Real-World Effectiveness and Safety of Risankizumab in Crohn’s Disease
08/21/2025
Rebecca Mashaw
Risankizumab demonstrates sustained clinical benefit and favorable safety in Crohn’s disease, including among ustekinumab-experienced patients.
Risankizumab demonstrates sustained clinical benefit and favorable safety in Crohn’s disease, including among ustekinumab-experienced patients.
Risankizumab demonstrates...
08/21/2025
Advances in Inflammatory Bowel Disease Network
FDA Alert
FDA Approves Both SC and IV Guselkumab for Crohn's Disease Among Adult Patients
03/24/2025
Rebecca Mashaw
This clearance follows last year's approval for ulcerative colitis and the first approval for subcutaneous and intravenous formulations to induce remission in adult patients with moderately to severely active Crohn's disease.
This clearance follows last year's approval for ulcerative colitis and the first approval for subcutaneous and intravenous formulations to induce remission in adult patients with moderately to severely active Crohn's disease.
This clearance follows last...
03/24/2025
Advances in Inflammatory Bowel Disease Network
News
Standard Dosing of Infliximab Effective for Steroid-Refractory ASUC
10/18/2024
Jessica Garlewicz
While infliximab proved safe and effective for inducing remission in acute severe ulcerative colitis, higher doses and varied induction strategies showed no significant change in response.
While infliximab proved safe and effective for inducing remission in acute severe ulcerative colitis, higher doses and varied induction strategies showed no significant change in response.
While infliximab proved safe and...
10/18/2024
Advances in Inflammatory Bowel Disease Network
FDA alert
FDA Alert
FDA Approves Guselkumab for Moderate to Severe Ulcerative Colitis
09/12/2024
Rebecca Mashaw
Johnson & Johnson’s guselkumab is the first and only fully-human, dual-acting monoclonal antibody that blocks IL-23 and binds to CD64.
Johnson & Johnson’s guselkumab is the first and only fully-human, dual-acting monoclonal antibody that blocks IL-23 and binds to CD64.
Johnson & Johnson’s guselkumab...
09/12/2024
Advances in Inflammatory Bowel Disease Network
FDA alert
FDA Alert
FDA Requires Warning Label Change for Thiopurines
08/13/2024
Rebecca Mashaw
The agency stated that rare cases of intrahepatic cholestasis of pregnancy have been reported among pregnant patients treated with thiopurines for inflammatory bowel disease and systemtic lupus erythematosus.
The agency stated that rare cases of intrahepatic cholestasis of pregnancy have been reported among pregnant patients treated with thiopurines for inflammatory bowel disease and systemtic lupus erythematosus.
The agency stated that rare...
08/13/2024
Advances in Inflammatory Bowel Disease Network
News
Upadacitinib vs Tofacitinib for Clinical Remission in Ulcerative Colitis
08/09/2024
Jolynn Tumolo
Investigators conducted a head-to-head trial of the 2 JAK inhibitors to determine which performed best in achieving steroid-free clinical remission among patients with ulcerative colitis
Investigators conducted a head-to-head trial of the 2 JAK inhibitors to determine which performed best in achieving steroid-free clinical remission among patients with ulcerative colitis
Investigators conducted a...
08/09/2024
Advances in Inflammatory Bowel Disease Network
News
FDA Approves Interchangeable Biosimilar for Ustekinumab
11/02/2023
The biosimilar was also approved to treat moderate to severe plaque psoriasis and active psoriatic arthritis.
The biosimilar was also approved to treat moderate to severe plaque psoriasis and active psoriatic arthritis.
The biosimilar was also approved...
11/02/2023
Advances in Inflammatory Bowel Disease Network
FDA alert
FDA Alert
FDA Approves Mirikizumab for Adults With Moderately to Severely Active Ulcerative Colitis
10/27/2023
Rebecca Mashaw
The LUCENT trial demonstrated the safety and efficacy of the interleukin-23/p19 subunit inhibitor.
The LUCENT trial demonstrated the safety and efficacy of the interleukin-23/p19 subunit inhibitor.
The LUCENT trial demonstrated...
10/27/2023
Advances in Inflammatory Bowel Disease Network
News
FDA Approves New Oral Treatment for Ulcerative Colitis
10/13/2023
Priyam Vora
The U.S. Food and Drug Administration approved etrasimod for the treatment of moderate to severe ulcerative colitis among adults.
The U.S. Food and Drug Administration approved etrasimod for the treatment of moderate to severe ulcerative colitis among adults.
The U.S. Food and Drug...
10/13/2023
Advances in Inflammatory Bowel Disease Network
Research Review
New Meta-Analysis Highlights Burden of MASLD Among IBD Patients
02/03/2026
Rebecca Mashaw
The study draws on data from more than 1.5 million individuals, providing the most extensive evidence yet on MASLD’s prevalence and associated factors in patients with Crohn’s disease and ulcerative colitis.
The study draws on data from more than 1.5 million individuals, providing the most extensive evidence yet on MASLD’s prevalence and associated factors in patients with Crohn’s disease and ulcerative colitis.
The study draws on data from...
02/03/2026
Gastroenterology
News
Medicare Will Cover GLP-1s for Obesity Under Deal with Pharma
11/06/2025
Rebecca Mashaw
Administration officials said the new lower prices also will be provided for Medicaid programs, with prices and timing decided state by state as they opt in.
Administration officials said the new lower prices also will be provided for Medicaid programs, with prices and timing decided state by state as they opt in.
Administration officials said...
11/06/2025
Advances in Inflammatory Bowel Disease Network
FDA alert
FDA Alert
FDA Approves Updated Indication for Upadacitinib in IBD
10/14/2025
Rebecca Mashaw
The new indication allows for upadacitinib therapy among patients who have received any approved systemic therapy for IBD “in the event TNF blockers are clinically inadvisable."
The new indication allows for upadacitinib therapy among patients who have received any approved systemic therapy for IBD “in the event TNF blockers are clinically inadvisable."
The new indication allows for...
10/14/2025
Advances in Inflammatory Bowel Disease Network
Research Highlights
Concomitant Medications Do Not Alter Efficacy of Advanced Therapies in Ulcerative Colitis, Study Finds
09/18/2025
Jessica Garlewicz
New study findings suggest that most baseline concomitant therapies do not require modification or exclusion when initiating advanced therapy in clinical trial settings.
New study findings suggest that most baseline concomitant therapies do not require modification or exclusion when initiating advanced therapy in clinical trial settings.
New study findings suggest that...
09/18/2025
Advances in Inflammatory Bowel Disease Network
Research Highlights
Persistent Prothrombotic State Observed in Patients With ASUC
09/04/2025
Rebecca Mashaw
New findings show patients with acute severe ulcerative colitis remain at elevated thrombotic risk for up to 12 weeks post-hospitalization.
New findings show patients with acute severe ulcerative colitis remain at elevated thrombotic risk for up to 12 weeks post-hospitalization.
New findings show patients with...
09/04/2025
Advances in Inflammatory Bowel Disease Network
Research Highlights
Upadacitinib Improves Outcomes in Fistulizing Crohn’s Disease
09/04/2025
Rebecca Mashaw
Patients with fistulizing Crohn’s disease achieved higher rates of fistula resolution and clinical response with upadacitinib versus placebo.
Patients with fistulizing Crohn’s disease achieved higher rates of fistula resolution and clinical response with upadacitinib versus placebo.
Patients with fistulizing...
09/04/2025
Advances in Inflammatory Bowel Disease Network
Research Highlights
Pelvic MRI Detects Subclinical Perianal Disease in Pediatric Crohn’s Disease
09/04/2025
Jessica Garlewicz
The study highlights a diagnostic blind spot in pediatric CD management and supports adding baseline pelvic MRI to initial workup, even in the absence of perianal symptoms.
The study highlights a diagnostic blind spot in pediatric CD management and supports adding baseline pelvic MRI to initial workup, even in the absence of perianal symptoms.
The study highlights a...
09/04/2025
Advances in Inflammatory Bowel Disease Network
Research Highlights
Mirikizumab Improves Quality of Life and Work Productivity in Moderate to Severe Crohn’s Disease
09/04/2025
Jessica Garlewicz
Study findings highlight mirikizumab as a therapeutic option that delivers not only symptom relief but also sustained improvements in quality of life and functional outcomes for patients with moderate to severe CD.
Study findings highlight mirikizumab as a therapeutic option that delivers not only symptom relief but also sustained improvements in quality of life and functional outcomes for patients with moderate to severe CD.
Study findings highlight...
09/04/2025
Advances in Inflammatory Bowel Disease Network
Research Highlights
Risankizumab Improves Symptom Resolution and Quality of Life in Ulcerative Colitis
09/04/2025
Jessica Garlewicz
Risankizumab led to earlier and sustained improvements in individual symptoms—including abdominal pain, bowel urgency, fecal incontinence, and sleep interruption
Risankizumab led to earlier and sustained improvements in individual symptoms—including abdominal pain, bowel urgency, fecal incontinence, and sleep interruption
Risankizumab led to earlier and...
09/04/2025
Advances in Inflammatory Bowel Disease Network
Research Highlights
Guselkumab Demonstrates Efficacy and Safety in Moderate-to-Severe Crohn’s Disease
09/04/2025
Jessica Garlewicz
The study met all primary and multiplicity-controlled secondary endpoints, including clinical and endoscopic outcomes through 48 weeks.
The study met all primary and multiplicity-controlled secondary endpoints, including clinical and endoscopic outcomes through 48 weeks.
The study met all primary and...
09/04/2025
Advances in Inflammatory Bowel Disease Network

Insights

IBD Drive time logo
Podcast
IBD Drive Time: Erin Forster, MD, on Risankizumab for Ulcerative Colitis
09/03/2024
Erin Forster, MD, MPH; Millie D. Long, MD, MPH; Raymond Cross, MD
Dr Erin Forster of the Medical University of South Carolina joins IBD Drive Time hosts Dr Millie Long and Dr Raymond Cross to review results of the trials for risankizumab in ulcerative colitis and discuss its positioning in treatment.
Dr Erin Forster of the Medical University of South Carolina joins IBD Drive Time hosts Dr Millie Long and Dr Raymond Cross to review results of the trials for risankizumab in ulcerative colitis and discuss its positioning in treatment.
Dr Erin Forster of the Medical...
09/03/2024
Advances in Inflammatory Bowel Disease Network
Shubha Bhat
Podcast
Shubha Bhat, PharmD, on the Role of the Clinical Pharmacist in IBD
07/25/2024
Dr Bhat reports on the recent systematic review and RAND consensus process to define the role of the clinical pharmacist in caring for patients with inflammatory bowel disease.
Dr Bhat reports on the recent systematic review and RAND consensus process to define the role of the clinical pharmacist in caring for patients with inflammatory bowel disease.
Dr Bhat reports on the recent...
07/25/2024
Advances in Inflammatory Bowel Disease Network
Jessica Allegretti
Video
Jessica Allegretti, MD, on Recent Advances in Anti-Interleukin Therapies
07/19/2024
Dr Allegretti provides key take-home points from her presentation at the AIBD regional meeting on how anti-interleukin therapies work to treat both Crohn's disease and ulcerative colitis.
Dr Allegretti provides key take-home points from her presentation at the AIBD regional meeting on how anti-interleukin therapies work to treat both Crohn's disease and ulcerative colitis.
Dr Allegretti provides key...
07/19/2024
Advances in Inflammatory Bowel Disease Network
Ed Loftus
Video
Edward Loftus, MD, on Upadacitinib in Crohn's Disease
06/06/2024
Dr Loftus recaps his poster presentation on a subanalysis from the upadacitinib phase 3 trials in Crohn's disease examining the effect on anxiety, depression, fatigue, and bowel urgency.
Dr Loftus recaps his poster presentation on a subanalysis from the upadacitinib phase 3 trials in Crohn's disease examining the effect on anxiety, depression, fatigue, and bowel urgency.
Dr Loftus recaps his poster...
06/06/2024
Advances in Inflammatory Bowel Disease Network
Miguel Regueiro MD
Conference Coverage
Miguel Regueiro, MD, on the SEQUENCE Study
06/03/2024
Miguel D. Regueiro, MD
Dr Regueiro recaps the results from the pivotal study comparing the effects of risankizumab with ustekinumab on key biomarkers of inflammatory bowel disease, which he presented at Digestive Disease Week 2024.
Dr Regueiro recaps the results from the pivotal study comparing the effects of risankizumab with ustekinumab on key biomarkers of inflammatory bowel disease, which he presented at Digestive Disease Week 2024.
Dr Regueiro recaps the results...
06/03/2024
Advances in Inflammatory Bowel Disease Network
Rishika Chugh
Podcast
Rishika Chugh, MD: Safety of Vedolizumab and Ustekinumab in Pregnancy
05/28/2024
Dr Chugh reviews the results of a recent study of the safety of ustekinumab and vedolizumab among pregnant patients with inflammatory bowel disease.
Dr Chugh reviews the results of a recent study of the safety of ustekinumab and vedolizumab among pregnant patients with inflammatory bowel disease.
Dr Chugh reviews the results of...
05/28/2024
Advances in Inflammatory Bowel Disease Network
Christina Ha
Video
Christina Ha, MD, on Anti-Integrins in IBD
04/27/2024
Dr Ha recaps her presentation from the AIBD regional on the use of anti-integrins, particularly vedolizumab, for treating IBD.
Dr Ha recaps her presentation from the AIBD regional on the use of anti-integrins, particularly vedolizumab, for treating IBD.
Dr Ha recaps her presentation...
04/27/2024
Advances in Inflammatory Bowel Disease Network
Ray
Video
Raymond Cross, MD, on JAK Inhibitors in IBD
04/27/2024
Dr Cross reviews his presentation from the AIBD regional meeting on the use, safety, and positioning of Janus kinase inhibitors for the treatment of IBD.
Dr Cross reviews his presentation from the AIBD regional meeting on the use, safety, and positioning of Janus kinase inhibitors for the treatment of IBD.
Dr Cross reviews his...
04/27/2024
Advances in Inflammatory Bowel Disease Network
Jordan Axelrad
Conference Coverage
Jordan Axelrad, MD, on S1P Receptor Modulators in IBD
04/06/2024
Dr Axelrad discusses his presentation at the AIBD regional meeting on the value and positioning of sphingosine 1-phosphate receptor modulators for the treatment of inflammatory bowel disease.
Dr Axelrad discusses his presentation at the AIBD regional meeting on the value and positioning of sphingosine 1-phosphate receptor modulators for the treatment of inflammatory bowel disease.
Dr Axelrad discusses his...
04/06/2024
Advances in Inflammatory Bowel Disease Network
IBD Drive time logo
Podcast
IBD Drive Time: Russell Cohen, MD, on New Therapies for IBD
12/20/2023
In this episode of IBD Drive Time, Dr Raymond Cross and Dr Russell Cohen review several new therapies and formulations that have been recently approved for treating inflammatory bowel disease and discuss how best to position these medications.
In this episode of IBD Drive Time, Dr Raymond Cross and Dr Russell Cohen review several new therapies and formulations that have been recently approved for treating inflammatory bowel disease and discuss how best to position these medications.
In this episode of IBD Drive...
12/20/2023
Advances in Inflammatory Bowel Disease Network
Conference Coverage
AIBD Poster Award Winner: Katherine Cates, MD
01/24/2026
Dr Cates describes her award-winning poster on the use of anal pap smears to identify patients at high risk of developing anal cancer and advance them to high-resolution anometry.
Dr Cates describes her award-winning poster on the use of anal pap smears to identify patients at high risk of developing anal cancer and advance them to high-resolution anometry.
Dr Cates describes her...
01/24/2026
Advances in Inflammatory Bowel Disease Network
Conference Coverage
AIBD Poster Award Winner: Dana Neugut, MD
01/24/2026
Dana Neugut, MD
Dr Neugut reviews her award-winning poster from AIBD on the association of Childhood Opportunity Index with time to infliximab discontinuation in pediatric patients with inflammatory bowel disease.
Dr Neugut reviews her award-winning poster from AIBD on the association of Childhood Opportunity Index with time to infliximab discontinuation in pediatric patients with inflammatory bowel disease.
Dr Neugut reviews her...
01/24/2026
Advances in Inflammatory Bowel Disease Network
Conference Coverage
AIBD Poster Award Winner: Ece Unal, MD
01/20/2026
Ece Unal, MD
Cleveland Clinic surgery resident Ece Unal, MD, gives an overview of her award-winning poster on a systematic review of excision of skin tags in perianal Crohn’s Disease, presented at the AIBD Annual Meeting.
Cleveland Clinic surgery resident Ece Unal, MD, gives an overview of her award-winning poster on a systematic review of excision of skin tags in perianal Crohn’s Disease, presented at the AIBD Annual Meeting.
Cleveland Clinic surgery...
01/20/2026
Advances in Inflammatory Bowel Disease Network
From the AIBD Open Air Studio
AIBD Poster Award Winner: Wei Wei Lee, MD
01/20/2026
Wei Wei Lee, MD
Dr Lee describes her award-winning poster presentation on the frequency of changes in diagnosis from ulcerative colitis to Crohn's disease among pediatric patients.
Dr Lee describes her award-winning poster presentation on the frequency of changes in diagnosis from ulcerative colitis to Crohn's disease among pediatric patients.
Dr Lee describes her...
01/20/2026
Advances in Inflammatory Bowel Disease Network
IBD Drive time logo
Expert Insights
IBD Drive Time: Raymond Cross, MD, on Ostomy Complications
01/13/2026
Raymond Cross, MD; Sara Horst, MD
In this episode of IBD Drive Time, Dr Raymond Cross switches seats and acts as the guest with Sara Horst, MD, as host, to discuss the complexities of ostomy complications.
In this episode of IBD Drive Time, Dr Raymond Cross switches seats and acts as the guest with Sara Horst, MD, as host, to discuss the complexities of ostomy complications.
In this episode of IBD Drive...
01/13/2026
Advances in Inflammatory Bowel Disease Network
Oriana Damas
From the AIBD Open Air Studio
The Sherman Emerging Leader Award: Oriana Damas, MD
12/29/2025
Oriana Damas, MD, MSCTI
Awarded the Sherman Emerging Leader Prize at the Advances in IBD annual meeting, Dr Oriana Damas encouraged others to use passion, dedication, and vision to move the field forward.
Awarded the Sherman Emerging Leader Prize at the Advances in IBD annual meeting, Dr Oriana Damas encouraged others to use passion, dedication, and vision to move the field forward.
Awarded the Sherman Emerging...
12/29/2025
Advances in Inflammatory Bowel Disease Network
Michael Kappelman
From the AIBD Open Air Studio
The Sherman Prize: Michael Kappelman, MD
12/29/2025
Michael Kappelman, MD
Dr Michael Kappelman, one of the Sherman Prize winners for 2025, speaks from the Open Air Studio at the Advances in IBD meeting about his clinical and research work with pediatric patients with ulcerative colitis or Crohn's disease.
Dr Michael Kappelman, one of the Sherman Prize winners for 2025, speaks from the Open Air Studio at the Advances in IBD meeting about his clinical and research work with pediatric patients with ulcerative colitis or Crohn's disease.
Dr Michael Kappelman, one of the...
12/29/2025
Advances in Inflammatory Bowel Disease Network
Scott Snapper
From the AIBD Open Air Studio
The Sherman Prize: Scott Snapper, MD
12/29/2025
Scott Snapper, MD
Sherman Prize winner Dr Scott Snapper reviewed his team's work on the genetics associated with IBD in children from the Open Air Studio at the Advances in IBD annual meeting.
Sherman Prize winner Dr Scott Snapper reviewed his team's work on the genetics associated with IBD in children from the Open Air Studio at the Advances in IBD annual meeting.
Sherman Prize winner Dr Scott...
12/29/2025
Advances in Inflammatory Bowel Disease Network
Corey & Miguel
From the AIBD Open Air Studio
Optimize or Switch Therapy? Siegel vs Regueiro Debate
12/23/2025
Miguel D. Regueiro, MD; Corey A. Siegel, MD, MS
For the 9th year, Drs Miguel Regueiro and Corey Siegel both claim victory in their annual debate—this time, about switching vs optimizing therapies—and remain friends.
For the 9th year, Drs Miguel Regueiro and Corey Siegel both claim victory in their annual debate—this time, about switching vs optimizing therapies—and remain friends.
For the 9th year, Drs Miguel...
12/23/2025
Advances in Inflammatory Bowel Disease Network
Ray Cross and Tina Ha
From the AIBD Open Air Studio
IBD Drive Time: Christina Ha, MD, on Positioning IBD Therapies
12/23/2025
Raymond Cross, MD; Christina Ha, MD
In the first-ever video version of the IBD Drive Time podcast, Drs Raymond Cross and Christina Ha discuss positioning IBD therapies from our Open Air Studio at the AIBD Annual Meeting.
In the first-ever video version of the IBD Drive Time podcast, Drs Raymond Cross and Christina Ha discuss positioning IBD therapies from our Open Air Studio at the AIBD Annual Meeting.
In the first-ever video version...
12/23/2025
Advances in Inflammatory Bowel Disease Network

Interactive Features

Quiz
Role of Biologic Agents in IBD
06/14/2023
Priyam Vora
Are biologic agents the ultimate answer in the treatment of intestinal inflammation? Test your knowledge here!
Are biologic agents the ultimate answer in the treatment of intestinal inflammation? Test your knowledge here!
Are biologic agents the ultimate...
06/14/2023
Advances in Inflammatory Bowel Disease Network
Quiz
Terminal Ileal Resection and CRC Risk
08/07/2025
Rebecca Mashaw
Is terminal ileum resection in patients with Crohn’s disease associated with colorectal cancer risk? See what recent research found by taking our quiz.
Is terminal ileum resection in patients with Crohn’s disease associated with colorectal cancer risk? See what recent research found by taking our quiz.
Is terminal ileum resection in...
08/07/2025
Gastroenterology
Quiz
Does Hormone Replacement Therapy Affect IBD?
07/18/2025
Can hormone replacement therapy help or harm disease activity among women with IBD? Our quiz will show the answer!
Can hormone replacement therapy help or harm disease activity among women with IBD? Our quiz will show the answer!
Can hormone replacement therapy...
07/18/2025
Advances in Inflammatory Bowel Disease Network
Quiz
Can Perspiration Reveal IBD Biomarkers?
07/18/2025
Can a wearable sensor help monitor disease activity in IBD--via sweat? Take our quiz to get the answer.
Can a wearable sensor help monitor disease activity in IBD--via sweat? Take our quiz to get the answer.
Can a wearable sensor help...
07/18/2025
Advances in Inflammatory Bowel Disease Network
Quiz
Making EHRs Work
07/01/2025
Rebecca Mashaw
Which of the following factors did clinicians say in a recent study is particularly important for EHR functionality in the context of IBD?
Which of the following factors did clinicians say in a recent study is particularly important for EHR functionality in the context of IBD?
Which of the following factors...
07/01/2025
Advances in Inflammatory Bowel Disease Network
Quiz
Do EHRs Help or Hinder in IBD Care?
07/01/2025
Rebecca Mashaw
According to a recent survey of clinicians who care for patients with inflammatory bowel disease, what percentage reported that their EHR system does not enhance patient care in IBD?
According to a recent survey of clinicians who care for patients with inflammatory bowel disease, what percentage reported that their EHR system does not enhance patient care in IBD?
According to a recent survey of...
07/01/2025
Advances in Inflammatory Bowel Disease Network
Quiz
Advanced Combination Treatment for Refractory IBD
07/01/2025
Rebecca Mashaw
A multicenter Canadian study to evaluate advanced combination treatment (ACT) in patients with refractory inflammatory bowel disease (IBD) arrived at which of the following conclusions?
A multicenter Canadian study to evaluate advanced combination treatment (ACT) in patients with refractory inflammatory bowel disease (IBD) arrived at which of the following conclusions?
A multicenter Canadian study to...
07/01/2025
Advances in Inflammatory Bowel Disease Network
Quiz
Hormone Replacement Impact on IBD
05/22/2025
Rebecca Mashaw
Does hormone replacement therapy have any effect on treatment for IBD among postmenopausal women? Take our quiz to find out!
Does hormone replacement therapy have any effect on treatment for IBD among postmenopausal women? Take our quiz to find out!
Does hormone replacement therapy...
05/22/2025
Advances in Inflammatory Bowel Disease Network
Quiz
Upper GI Crohn's Disease
03/18/2025
Rebecca Mashaw
How much do you know about upper GI Crohn's disease? Take our quiz to check your knowledge!
How much do you know about upper GI Crohn's disease? Take our quiz to check your knowledge!
How much do you know about upper...
03/18/2025
Advances in Inflammatory Bowel Disease Network
Quiz
Preoperative Nutrition for Crohn’s Disease Patients
03/18/2025
Rebecca Mashaw
What is one benefit of preoperative exclusive enteral nutrition for Crohn’s disease patients? Take our quiz to find out if you know the answer!
What is one benefit of preoperative exclusive enteral nutrition for Crohn’s disease patients? Take our quiz to find out if you know the answer!
What is one benefit of...
03/18/2025
Advances in Inflammatory Bowel Disease Network
Quiz
Risk Factors for Surgery in Crohn’s Disease
02/26/2025
Rebecca Mashaw
Estimates vary but indicate that half or more of patients with Crohn's disease will require surgery at some point in their disease course. Do you know which factors place your patients at high risk for surgery? Take our quiz to find out!
Estimates vary but indicate that half or more of patients with Crohn's disease will require surgery at some point in their disease course. Do you know which factors place your patients at high risk for surgery? Take our quiz to find out!
Estimates vary but indicate that...
02/26/2025
Advances in Inflammatory Bowel Disease Network

Latest News

FDA alert
FDA Alert
FDA Approves Updated Indication for Upadacitinib in IBD
10/14/2025
Rebecca Mashaw
The new indication allows for upadacitinib therapy among patients who have received any approved systemic therapy for IBD “in the event TNF blockers are clinically inadvisable."
The new indication allows for upadacitinib therapy among patients who have received any approved systemic therapy for IBD “in the event TNF blockers are clinically inadvisable."
The new indication allows for...
10/14/2025
Advances in Inflammatory Bowel Disease Network
Research Highlights
Real-World Effectiveness and Safety of Risankizumab in Crohn’s Disease
08/21/2025
Rebecca Mashaw
Risankizumab demonstrates sustained clinical benefit and favorable safety in Crohn’s disease, including among ustekinumab-experienced patients.
Risankizumab demonstrates sustained clinical benefit and favorable safety in Crohn’s disease, including among ustekinumab-experienced patients.
Risankizumab demonstrates...
08/21/2025
Advances in Inflammatory Bowel Disease Network
FDA Alert
FDA Approves Both SC and IV Guselkumab for Crohn's Disease Among Adult Patients
03/24/2025
Rebecca Mashaw
This clearance follows last year's approval for ulcerative colitis and the first approval for subcutaneous and intravenous formulations to induce remission in adult patients with moderately to severely active Crohn's disease.
This clearance follows last year's approval for ulcerative colitis and the first approval for subcutaneous and intravenous formulations to induce remission in adult patients with moderately to severely active Crohn's disease.
This clearance follows last...
03/24/2025
Advances in Inflammatory Bowel Disease Network
News
Standard Dosing of Infliximab Effective for Steroid-Refractory ASUC
10/18/2024
Jessica Garlewicz
While infliximab proved safe and effective for inducing remission in acute severe ulcerative colitis, higher doses and varied induction strategies showed no significant change in response.
While infliximab proved safe and effective for inducing remission in acute severe ulcerative colitis, higher doses and varied induction strategies showed no significant change in response.
While infliximab proved safe and...
10/18/2024
Advances in Inflammatory Bowel Disease Network
FDA alert
FDA Alert
FDA Approves Guselkumab for Moderate to Severe Ulcerative Colitis
09/12/2024
Rebecca Mashaw
Johnson & Johnson’s guselkumab is the first and only fully-human, dual-acting monoclonal antibody that blocks IL-23 and binds to CD64.
Johnson & Johnson’s guselkumab is the first and only fully-human, dual-acting monoclonal antibody that blocks IL-23 and binds to CD64.
Johnson & Johnson’s guselkumab...
09/12/2024
Advances in Inflammatory Bowel Disease Network
FDA alert
FDA Alert
FDA Requires Warning Label Change for Thiopurines
08/13/2024
Rebecca Mashaw
The agency stated that rare cases of intrahepatic cholestasis of pregnancy have been reported among pregnant patients treated with thiopurines for inflammatory bowel disease and systemtic lupus erythematosus.
The agency stated that rare cases of intrahepatic cholestasis of pregnancy have been reported among pregnant patients treated with thiopurines for inflammatory bowel disease and systemtic lupus erythematosus.
The agency stated that rare...
08/13/2024
Advances in Inflammatory Bowel Disease Network
News
Upadacitinib vs Tofacitinib for Clinical Remission in Ulcerative Colitis
08/09/2024
Jolynn Tumolo
Investigators conducted a head-to-head trial of the 2 JAK inhibitors to determine which performed best in achieving steroid-free clinical remission among patients with ulcerative colitis
Investigators conducted a head-to-head trial of the 2 JAK inhibitors to determine which performed best in achieving steroid-free clinical remission among patients with ulcerative colitis
Investigators conducted a...
08/09/2024
Advances in Inflammatory Bowel Disease Network
News
FDA Approves Interchangeable Biosimilar for Ustekinumab
11/02/2023
The biosimilar was also approved to treat moderate to severe plaque psoriasis and active psoriatic arthritis.
The biosimilar was also approved to treat moderate to severe plaque psoriasis and active psoriatic arthritis.
The biosimilar was also approved...
11/02/2023
Advances in Inflammatory Bowel Disease Network
FDA alert
FDA Alert
FDA Approves Mirikizumab for Adults With Moderately to Severely Active Ulcerative Colitis
10/27/2023
Rebecca Mashaw
The LUCENT trial demonstrated the safety and efficacy of the interleukin-23/p19 subunit inhibitor.
The LUCENT trial demonstrated the safety and efficacy of the interleukin-23/p19 subunit inhibitor.
The LUCENT trial demonstrated...
10/27/2023
Advances in Inflammatory Bowel Disease Network
News
FDA Approves New Oral Treatment for Ulcerative Colitis
10/13/2023
Priyam Vora
The U.S. Food and Drug Administration approved etrasimod for the treatment of moderate to severe ulcerative colitis among adults.
The U.S. Food and Drug Administration approved etrasimod for the treatment of moderate to severe ulcerative colitis among adults.
The U.S. Food and Drug...
10/13/2023
Advances in Inflammatory Bowel Disease Network
Research Review
New Meta-Analysis Highlights Burden of MASLD Among IBD Patients
02/03/2026
Rebecca Mashaw
The study draws on data from more than 1.5 million individuals, providing the most extensive evidence yet on MASLD’s prevalence and associated factors in patients with Crohn’s disease and ulcerative colitis.
The study draws on data from more than 1.5 million individuals, providing the most extensive evidence yet on MASLD’s prevalence and associated factors in patients with Crohn’s disease and ulcerative colitis.
The study draws on data from...
02/03/2026
Gastroenterology
News
Medicare Will Cover GLP-1s for Obesity Under Deal with Pharma
11/06/2025
Rebecca Mashaw
Administration officials said the new lower prices also will be provided for Medicaid programs, with prices and timing decided state by state as they opt in.
Administration officials said the new lower prices also will be provided for Medicaid programs, with prices and timing decided state by state as they opt in.
Administration officials said...
11/06/2025
Advances in Inflammatory Bowel Disease Network
FDA alert
FDA Alert
FDA Approves Updated Indication for Upadacitinib in IBD
10/14/2025
Rebecca Mashaw
The new indication allows for upadacitinib therapy among patients who have received any approved systemic therapy for IBD “in the event TNF blockers are clinically inadvisable."
The new indication allows for upadacitinib therapy among patients who have received any approved systemic therapy for IBD “in the event TNF blockers are clinically inadvisable."
The new indication allows for...
10/14/2025
Advances in Inflammatory Bowel Disease Network
Research Highlights
Concomitant Medications Do Not Alter Efficacy of Advanced Therapies in Ulcerative Colitis, Study Finds
09/18/2025
Jessica Garlewicz
New study findings suggest that most baseline concomitant therapies do not require modification or exclusion when initiating advanced therapy in clinical trial settings.
New study findings suggest that most baseline concomitant therapies do not require modification or exclusion when initiating advanced therapy in clinical trial settings.
New study findings suggest that...
09/18/2025
Advances in Inflammatory Bowel Disease Network
Research Highlights
Persistent Prothrombotic State Observed in Patients With ASUC
09/04/2025
Rebecca Mashaw
New findings show patients with acute severe ulcerative colitis remain at elevated thrombotic risk for up to 12 weeks post-hospitalization.
New findings show patients with acute severe ulcerative colitis remain at elevated thrombotic risk for up to 12 weeks post-hospitalization.
New findings show patients with...
09/04/2025
Advances in Inflammatory Bowel Disease Network
Research Highlights
Upadacitinib Improves Outcomes in Fistulizing Crohn’s Disease
09/04/2025
Rebecca Mashaw
Patients with fistulizing Crohn’s disease achieved higher rates of fistula resolution and clinical response with upadacitinib versus placebo.
Patients with fistulizing Crohn’s disease achieved higher rates of fistula resolution and clinical response with upadacitinib versus placebo.
Patients with fistulizing...
09/04/2025
Advances in Inflammatory Bowel Disease Network
Research Highlights
Pelvic MRI Detects Subclinical Perianal Disease in Pediatric Crohn’s Disease
09/04/2025
Jessica Garlewicz
The study highlights a diagnostic blind spot in pediatric CD management and supports adding baseline pelvic MRI to initial workup, even in the absence of perianal symptoms.
The study highlights a diagnostic blind spot in pediatric CD management and supports adding baseline pelvic MRI to initial workup, even in the absence of perianal symptoms.
The study highlights a...
09/04/2025
Advances in Inflammatory Bowel Disease Network
Research Highlights
Mirikizumab Improves Quality of Life and Work Productivity in Moderate to Severe Crohn’s Disease
09/04/2025
Jessica Garlewicz
Study findings highlight mirikizumab as a therapeutic option that delivers not only symptom relief but also sustained improvements in quality of life and functional outcomes for patients with moderate to severe CD.
Study findings highlight mirikizumab as a therapeutic option that delivers not only symptom relief but also sustained improvements in quality of life and functional outcomes for patients with moderate to severe CD.
Study findings highlight...
09/04/2025
Advances in Inflammatory Bowel Disease Network
Research Highlights
Risankizumab Improves Symptom Resolution and Quality of Life in Ulcerative Colitis
09/04/2025
Jessica Garlewicz
Risankizumab led to earlier and sustained improvements in individual symptoms—including abdominal pain, bowel urgency, fecal incontinence, and sleep interruption
Risankizumab led to earlier and sustained improvements in individual symptoms—including abdominal pain, bowel urgency, fecal incontinence, and sleep interruption
Risankizumab led to earlier and...
09/04/2025
Advances in Inflammatory Bowel Disease Network
Research Highlights
Guselkumab Demonstrates Efficacy and Safety in Moderate-to-Severe Crohn’s Disease
09/04/2025
Jessica Garlewicz
The study met all primary and multiplicity-controlled secondary endpoints, including clinical and endoscopic outcomes through 48 weeks.
The study met all primary and multiplicity-controlled secondary endpoints, including clinical and endoscopic outcomes through 48 weeks.
The study met all primary and...
09/04/2025
Advances in Inflammatory Bowel Disease Network

Latest Podcasts

IBD Drive time logo
Podcast
IBD Drive Time: Erin Forster, MD, on Risankizumab for Ulcerative Colitis
09/03/2024
Erin Forster, MD, MPH; Millie D. Long, MD, MPH; Raymond Cross, MD
Dr Erin Forster of the Medical University of South Carolina joins IBD Drive Time hosts Dr Millie Long and Dr Raymond Cross to review results of the trials for risankizumab in ulcerative colitis and discuss its positioning in treatment.
Dr Erin Forster of the Medical University of South Carolina joins IBD Drive Time hosts Dr Millie Long and Dr Raymond Cross to review results of the trials for risankizumab in ulcerative colitis and discuss its positioning in treatment.
Dr Erin Forster of the Medical...
09/03/2024
Advances in Inflammatory Bowel Disease Network
Shubha Bhat
Podcast
Shubha Bhat, PharmD, on the Role of the Clinical Pharmacist in IBD
07/25/2024
Dr Bhat reports on the recent systematic review and RAND consensus process to define the role of the clinical pharmacist in caring for patients with inflammatory bowel disease.
Dr Bhat reports on the recent systematic review and RAND consensus process to define the role of the clinical pharmacist in caring for patients with inflammatory bowel disease.
Dr Bhat reports on the recent...
07/25/2024
Advances in Inflammatory Bowel Disease Network
Rishika Chugh
Podcast
Rishika Chugh, MD: Safety of Vedolizumab and Ustekinumab in Pregnancy
05/28/2024
Dr Chugh reviews the results of a recent study of the safety of ustekinumab and vedolizumab among pregnant patients with inflammatory bowel disease.
Dr Chugh reviews the results of a recent study of the safety of ustekinumab and vedolizumab among pregnant patients with inflammatory bowel disease.
Dr Chugh reviews the results of...
05/28/2024
Advances in Inflammatory Bowel Disease Network
IBD Drive time logo
Podcast
IBD Drive Time: Russell Cohen, MD, on New Therapies for IBD
12/20/2023
In this episode of IBD Drive Time, Dr Raymond Cross and Dr Russell Cohen review several new therapies and formulations that have been recently approved for treating inflammatory bowel disease and discuss how best to position these medications.
In this episode of IBD Drive Time, Dr Raymond Cross and Dr Russell Cohen review several new therapies and formulations that have been recently approved for treating inflammatory bowel disease and discuss how best to position these medications.
In this episode of IBD Drive...
12/20/2023
Advances in Inflammatory Bowel Disease Network
Bruce Sands
Podcast
Bruce Sands, MD, on the VEGA Study of Combination Biologic Therapy in UC
12/19/2022
Dr Sands provides an overview of the VEGA study, the first of its kind to combine 2 biologic agents to attempt to achieve higher rates of remission among patients with ulcerative colitis.
Dr Sands provides an overview of the VEGA study, the first of its kind to combine 2 biologic agents to attempt to achieve higher rates of remission among patients with ulcerative colitis.
Dr Sands provides an overview of...
12/19/2022
Advances in Inflammatory Bowel Disease Network
IBD Drive time logo
Expert Insights
IBD Drive Time: Raymond Cross, MD, on Ostomy Complications
01/13/2026
Raymond Cross, MD; Sara Horst, MD
In this episode of IBD Drive Time, Dr Raymond Cross switches seats and acts as the guest with Sara Horst, MD, as host, to discuss the complexities of ostomy complications.
In this episode of IBD Drive Time, Dr Raymond Cross switches seats and acts as the guest with Sara Horst, MD, as host, to discuss the complexities of ostomy complications.
In this episode of IBD Drive...
01/13/2026
Advances in Inflammatory Bowel Disease Network
IBD Drive time logo
Conference Coverage
IBD Drive Time: The Best of ACG With Dr Sara Horst
12/01/2025
Raymond Cross, MD; Sara Horst, MD
Dr Sara Horst joins IBD Drive Time host Dr Raymond Cross to review their choices for the best presentations from the American College of Gastroenterology annual meeting.
Dr Sara Horst joins IBD Drive Time host Dr Raymond Cross to review their choices for the best presentations from the American College of Gastroenterology annual meeting.
Dr Sara Horst joins IBD Drive...
12/01/2025
Advances in Inflammatory Bowel Disease Network
IBD Drive Time
Podcast
IBD Drive Time: Freddy Caldera, MD, on Vaccines for Patients With IBD
11/03/2025
Raymond Cross, MD; Freddy Caldera, DO
Freddy Caldera, DO, returns to talk to IBD Drive Time host Raymond Cross, MD, about the best current recommendations for patients with IBD in the midst of controversy and confusion.
Freddy Caldera, DO, returns to talk to IBD Drive Time host Raymond Cross, MD, about the best current recommendations for patients with IBD in the midst of controversy and confusion.
Freddy Caldera, DO, returns to...
11/03/2025
Advances in Inflammatory Bowel Disease Network
IBD Drive Time
Podcast
IBD Drive Time: Megan Riehl, PsyD, on Mental Health and IBD
10/22/2025
Raymond Cross, MD; Megan Riehl, PsyD
Clinical psychologist Megan Riehl, Psy D, talks with IBD Drive Time host Raymond Cross, MD, about the prevalence of anxiety and depression and even post-traumatic stress disorder among patients with inflammatory bowel disease--and how...
Clinical psychologist Megan Riehl, Psy D, talks with IBD Drive Time host Raymond Cross, MD, about the prevalence of anxiety and depression and even post-traumatic stress disorder among patients with inflammatory bowel disease--and how...
Clinical psychologist Megan...
10/22/2025
Advances in Inflammatory Bowel Disease Network
IBD Drive Time
Podcast
IBD Drive Time: Florian Rieder, MD, on Stricturing and Penetrating Crohn's Disease
10/06/2025
Raymond Cross, MD; Florian Rieder
Host Raymond Cross, MD, welcomes back Dr Florian Rieder, an internationally recognized expert in penetrating and stricturing complications of Crohn's disease, to talk about diagnosing, performing endoscopy, and treating this challenging...
Host Raymond Cross, MD, welcomes back Dr Florian Rieder, an internationally recognized expert in penetrating and stricturing complications of Crohn's disease, to talk about diagnosing, performing endoscopy, and treating this challenging...
Host Raymond Cross, MD, welcomes...
10/06/2025
Advances in Inflammatory Bowel Disease Network
IBD Drive time logo
Podcast
IBD Drive Time: Jason Schairer, MD, on Extraintestinal Manifestations in IBD
09/25/2025
Jason Schairer, MD; Raymond Cross, MD
Host Raymond Cross, MD, and guest Dr Jason Schairer discuss the varieties of extraintestinal manifestations that may be seen in patients with IBD, how to diagnose them and when to rely on colleagues in dermatology, ophthalmology, and...
Host Raymond Cross, MD, and guest Dr Jason Schairer discuss the varieties of extraintestinal manifestations that may be seen in patients with IBD, how to diagnose them and when to rely on colleagues in dermatology, ophthalmology, and...
Host Raymond Cross, MD, and...
09/25/2025
Advances in Inflammatory Bowel Disease Network
IBD Drive time logo
Podcast
Ryan Ungaro, MD, on Perturbances in Metabolic Pathways in IBD
09/02/2025
Raymond Cross, MD; Ryan Ungaro
Dr Raymond Cross discusses with Dr Ryan Ungaro how the Mount Sinai Crohn's and Colitis Registry, a prospective observational cohort, is being studied to determine if its detailed clinical information and omics data collected can identify new...
Dr Raymond Cross discusses with Dr Ryan Ungaro how the Mount Sinai Crohn's and Colitis Registry, a prospective observational cohort, is being studied to determine if its detailed clinical information and omics data collected can identify new...
Dr Raymond Cross discusses with...
09/02/2025
Advances in Inflammatory Bowel Disease Network
IBD Drive Time
Podcast
IBD Drive Time: Anita Afzali, MD, on the ACG Guidelines for Crohn's Disease
08/18/2025
Raymond Cross, MD; Anita Afzali
Dr Anita Afzali reviews with Dr Raymond Cross the updated guidelines for managing Crohn's disease from the American College of Gastroenterology,
Dr Anita Afzali reviews with Dr Raymond Cross the updated guidelines for managing Crohn's disease from the American College of Gastroenterology,
Dr Anita Afzali reviews with Dr...
08/18/2025
Advances in Inflammatory Bowel Disease Network
IBD Drive time logo
Podcast
IBD Drive Time: David Rubin, MD, on the ACG Guidelines for Ulcerative Colitis
08/04/2025
David T. Rubin, MD; Raymond Cross, MD
Host Raymond Cross, MD, discusses the updates in the American College of Gastroenterology guideline on managing ulcerative colitis with first author David Rubin, MD.
Host Raymond Cross, MD, discusses the updates in the American College of Gastroenterology guideline on managing ulcerative colitis with first author David Rubin, MD.
Host Raymond Cross, MD,...
08/04/2025
Advances in Inflammatory Bowel Disease Network
IBD Drive time logo
Podcast
IBD Drive Time: Corey Siegel, MD, on Defining Quality Care for IBD
07/15/2025
Raymond Cross, MD; Corey A. Siegel, MD, MS
Host Raymond Cross, MD, and Dr Corey Siegel delve into the factors that constitute quality care for patients with IBD today, and how the definition of quality care has evolved over time.
Host Raymond Cross, MD, and Dr Corey Siegel delve into the factors that constitute quality care for patients with IBD today, and how the definition of quality care has evolved over time.
Host Raymond Cross, MD, and Dr...
07/15/2025
Advances in Inflammatory Bowel Disease Network

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use